Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non-Small Cell Lung Cancers: A Multicenter, Retrospective Analysis.

ABSTRACT: This multicenter retrospective study analyzed data from 1266 patients with advanced non-small cell lung cancer (NSCLC) across five leading hospitals in China. The aim was to evaluate survival outcomes and safety profiles of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The main outcomes included overall survival (OS) and progression-free survival (PFS), while the secondary endpoint was adverse events. Kaplan-Meier survival analysis, univariate and multivariate Cox regression modeling, and propensity score matching (PSM) analyses were performed to compare the real-world efficacies of PD-1 and PD-L1. Patients receiving PD-1 inhibitors had significantly longer median OS compared with those treated with PD-L1 inhibitors (28.2 versus [vs.] 24.6 months; ha

SUBMITTER: Gan J 

PROVIDER: S-EPMC12618853 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature